ZHUOHONG CHAOYUAN

ZHUOHONG CHAOYUAN Biotechnology Co., Ltd. is committed to solving the global industry challenge of increasing the production of phenolic and terpenoid compounds through "AI + synthetic biology technology." The company's core business focuses on the platform-based product development of terpenoids such as monoterpenes and sesquiterpenes using its self-developed proprietary strains. At the same time, it employs cutting-edge synthetic biology methods to conduct in-depth research and development on the core molecules of traditional Chinese medicine for blood circulation. By constructing a broad-spectrum toxin-resistant proprietary strain, the company addresses the cytotoxicity issue of terpenoids, with its resistance to common monoterpenes or sesquiterpenes being over 100 times higher than that of well-known model strains like E. coli and Saccharomyces cerevisiae. Currently, the company has more than 30 terpenoid products under development, with 12 products having completed pilot-scale trials, and the pilot data ranks among the best globally. These products cover key areas such as flavors and fragrances, food supplements, pharmaceuticals, high-energy fuels, and chemical intermediates, offering broad market application prospects. The company’s overall development strategy closely aligns with China’s "Dual Carbon Goals," driven by innovation to achieve green alternatives to traditional petrochemical products, promote industrial transformation and upgrading, and contribute positively to sustainable development.